Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate

Executive Summary

A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.

You may also be interested in...



Flexibility Or Formal Pathway? Avycaz Suggests FDA Doesn't Need Congress To Expedite Limited Use Antibiotics

FDA steered Actavis' antibiotic Avycaz to approval for limited use based on limited data through the 505(b)(2) pathway, helped along by the agency's regulatory flexibility for medically important agents – making the Limited Population Antibiotic Development pathway under discussion on Capitol Hill look redundant.

Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult

Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel